Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CUL4A | Q13619 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.44 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
| ▸ | GBA1 | P04062 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5653005 | 0.96 | MAPT (0.47) | CUL4AMAPTALDH1A1ADRB1SIRT6 | |
| SCHEMBL223024 | 0.96 | MAPT (0.47) | CUL4AMAPTALDH1A1ADRB1SIRT6 | |
| SCHEMBL1092846 | 0.96 | MAPT (0.47) | CUL4AMAPTALDH1A1ADRB1SIRT6 | |
| Methoxymethane SCHEMBL5822675 | 0.91 | MAPT (0.48) | CUL4AMAPTALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL6714741 | 0.86 | ALDH1A1 (0.53) | MAPTALDH1A1LMNASIRT6POLB | |
| SCHEMBL12006068 | 0.82 | MAPT (0.49) | MAPTALDH1A1LMNAHRH3 | |
| SCHEMBL2886399 | 0.82 | MAPT (0.49) | MAPTALDH1A1LMNAHRH3 | |
| SCHEMBL28185991 | 0.81 | MAPT (0.47) | MAPTALDH1A1LMNAPOLBSMN1; SMN2 | |
| SCHEMBL6095682 | 0.81 | MAPT (0.47) | MAPTALDH1A1LMNAADRB1SIRT6 | |
| SCHEMBL13292851 | 0.81 | KMT2A (0.50) | MAPTALDH1A1LMNASIRT6SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8476336-B2 | Ophthalmologic composition and ophthalmologic lens | ACRI.TEC GMBH (DE) | 2013-07-02 | — | — | US | disclosed |
| US-8476336-B2 | Ophthalmologic composition and ophthalmologic lens | ACRI.TEC GMBH (DE) | 2013-07-02 | — | — | US | disclosed |
| EP-2199834-B1 | Ophthalmological composition and ophthalmologic lens | ZEISS CARL MEDITEC AG (DE) | 2012-07-25 | — | — | EP | disclosed |
| EP-2199834-B1 | Ophthalmological composition and ophthalmologic lens | ZEISS CARL MEDITEC AG (DE) | 2012-07-25 | — | — | EP | disclosed |
| US-20100160482-A1 | Ophthalmologic Composition And Ophthalmologic Lens | CARL ZEISS MEDITEC AG (DE) | 2010-06-24 | — | — | US | disclosed |
| US-20100160482-A1 | Ophthalmologic Composition And Ophthalmologic Lens | CARL ZEISS MEDITEC AG (DE) | 2010-06-24 | — | — | US | disclosed |
| EP-2199834-A1 | Ophthalmological composition and ophthalmologic lens | *Acri. Tec GmbH (DE) | 2010-06-23 | — | — | EP | disclosed |
| EP-2199834-A1 | Ophthalmological composition and ophthalmologic lens | *Acri. Tec GmbH (DE) | 2010-06-23 | — | — | EP | disclosed |
| US-20100016357-A1 | Use of Beta-Aminoalcohols for the Treatment of Inflammatory Disorders and Pain | SOSEI R & D LTD. (GB) | 2010-01-21 | — | — | US | disclosed |
| EP-1993544-A1 | THE USE OF BETA-AMINOALCOHOLS FOR THE TREATMENT OF INFLAMMATORY DISORDERS AND PAIN | Sosei R&D Ltd. (GB) | 2008-11-26 | — | — | EP | disclosed |
| EP-0964864-B1 | PYRIDO 2,3-D PYRIMIDINES AND 4-AMINOPYRIMIDINES AS INHIBITORS OF CELLULAR PROLIFERATION | WARNER LAMBERT CO (US) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007102011-A1 | THE USE OF BETA-AMINOALCOHOLS FOR THE TREATMENT OF INFLAMMATORY DISORDERS AND PAIN | SOSEI R & D LTD. (GB) | 2007-09-13 | — | — | WO | disclosed |
| EP-1806348-A2 | Pyrido (2,3-D)Pyrimidines as inhibitors of cellular proliferation | Warner-Lambert Company LLC (US) | 2007-07-11 | — | — | EP | disclosed |
| US-20040224958-A1 | Pyridopyrimidinone derivatives for treatment of neurodegenerative disease | BOOTH RICHARD JOHN (US) | 2004-11-11 | — | — | US | disclosed |
| CN-1433417-A | Pyridopyrimidinone derivatives for treatment of neurodegenerative disease | WARNER LAMBERT CO (US) | 2003-07-30 | — | — | CN | disclosed |
| US-6498163-B1 | POTENT INHIBITORS OF CYCLIN-DEPENDENT KINASES AND GROWTH FACTOR MEDIATED KINASES; CANCER, RESTENOSIS, ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY | 2002-12-24 | — | — | US | disclosed |
| EP-1255755-A1 | PYRIDOPYRIMIDINONE DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASE | WARNER-LAMBERT COMPANY (US) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001055148-A1 | PYRIDOPYRIMIDINONE DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASE | WARNER-LAMBERT COMPANY (US) | 2001-08-02 | — | — | WO | disclosed |
| EP-0964864-A2 | PYRIDO 2,3-D] PYRIMIDINES AND 4-AMINOPYRIMIDINES AS INHIBITORS OF CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 1999-12-22 | — | — | EP | disclosed |
| WO-1998033798-A2 | PYRIDO[2,3-D]PYRIMIDINES AND 4-AMINO-PYRIMIDINES AS INHIBITORS OF CELL PROLIFERATION | WARNER LAMBERT COMPANY (US) | 1998-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224958-A1 | Pyridopyrimidinone derivatives for treatment of neurodegenerative disease | CDK4, CDKL1, CCNT1 | CUL4A 3051/4885MAPT 2259/4885ALDH1A1 1162/4885 |
| US-20100160482-A1 | Ophthalmologic Composition And Ophthalmologic Lens | NR2E3, NR1H2, NR5A2 | CUL4A 3636/4885MAPT 2745/4885ALDH1A1 2628/4885 |
| US-20100016357-A1 | Use of Beta-Aminoalcohols for the Treatment of Inflammatory Disorders and Pain | HRH3, HRH2, HRH1 | CUL4A 3540/4885MAPT 4235/4885ALDH1A1 1467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.